Neurocrine (NBIX) Q3 2026 Earnings Call Transcript

Neurocrine reported Q3 2026 revenue of $1.1 billion, up 41% year over year, and non-GAAP diluted EPS of $3.29 versus $2.17 a year earlier. INGREZZA sales rose 17% to $801 million, and the company raised its 2026 sales guidance to $2.90 billion–$2.925 billion; management expects double-digit 2027 volume growth to offset mid- to high-single-digit net pricing headwinds. CRENESSITY sales were $211 million and VYKAT XR sales were $107 million, although management said safety-related external events could delay VYKAT XR’s growth trajectory. The company generated $400 million in operating cash flow and repurchased $100 million of shares, while highlighting Phase 3 readouts planned for 2027.

Analysis

The key underwriting question is whether volume growth can outrun increasingly explicit pricing pressure without requiring a disproportionate increase in commercial spend. For INGREZZA, payer access appears supportive, but mid- to high-single-digit net-price erosion means prescription growth will translate into a smaller revenue gain; the $20 million order-timing benefit also shifts reported sales between quarters rather than adding demand. Watch net sales and gross-to-net commentary, not prescription records alone.

VYKAT XR is the main near-term asymmetry: real-world safety concerns can affect physician confidence and starts before any formal label action, while discontinuations from the launch cohort may obscure underlying demand. The planned complex-comorbidity study is useful evidence generation, not a near-term label-expansion catalyst. CRENESSITY offers a steadier rare-disease growth leg, but future competition from Vertex and Crinetics could pressure adoption if their efficacy, convenience, or safety profiles prove competitive.

The market may be over-crediting pipeline breadth: six Phase I initiations and five Phase II starts indicate activity, not probability-adjusted value. The 2027 osavampator and direclidine Phase III readouts are the material multiple catalysts; failure or tolerability concerns could overwhelm incremental commercial execution. Conversely, a differentiated tolerability profile for direclidine would matter in a crowded schizophrenia market. Cash is materially lower than at year-end; verify acquisition-related uses, ongoing cash conversion, and capital allocation before treating buybacks as durable excess-return capacity. The $2.2 billion VYKAT intangible also creates a long-lived GAAP amortization burden, making non-GAAP leverage a less complete measure of economics.

Key Decisions for Investors

• Maintain a constructive NBIX bias, but add on post-earnings weakness rather than chasing the quarter; reassess after February 2027 guidance. Falsify the view if INGREZZA volume growth fails to offset net-price erosion or guidance implies revenue deceleration.
• Treat VYKAT XR as a watch item, not a standalone growth thesis: monitor quarterly patient net adds, discontinuations, and safety communications or FDA action. A sustained decline in net adds or a label change would weaken the growth case.
• Keep CRENESSITY in the positive thesis, while tracking competitor trial data and evidence of deeper prescribing/persistence; revise the long-term adoption view if patient additions or persistency weaken.
• Do not pay materially for pipeline optionality before data. Re-underwrite NBIX around the 2027 Phase III readouts for osavampator and direclidine, with efficacy and tolerability—not trial initiation counts—as the decision points.